Gianna is an associate editor of The American Journal of Managed Care® (AJMC®). She has been working on AJMC® since 2019 and has a BA in philosophy and journalism & professional writing from The College of New Jersey.
Treatment guidelines for comorbid depression and migraine are warranted to ensure optimal efficacy and avoid possible pitfalls in psychopharmacotherapy, according to study results.
Treatment guidelines for comorbid depression and migraine are warranted to ensure optimal efficacy and avoid possible pitfalls in psychopharmacotherapy, including serotonin syndrome, according to results of a multicenter study published in the International Journal od Neuropsychopharmacology.
Cross-sectional studies have found major depressive disorder (MDD) and headache disorders, such as migraine, routinely co-occur, while longitudinal studies indicate a reciprocal or bidirectional relationship between the disorders.
“Shared etiologic mechanisms include alterations in serotonergic and dopaminergic pathways that are partly reflected in treatment options for either disease as well as fluctuations in ovarian hormones and a dysregulation of the hypothalamic-pituitary-adrenal axis,” researchers wrote.
To better understand patients who suffer a comorbidity of the disorders, researchers conducted an international, multicenter, noninterventional, cross-sectional trial across 10 sites in Europe. Specifically, investigators hoped to increase knowledge on differences in sociodemographic, clinical, psychopharmacotherapuetic, and response characteristics between individuals with MDD with or without comorbid migraine.
Between November 2012 and February 2016, a total of 1419 patients with MDD representative of those encountered in clinical settings were enrolled in the study. Patients were recruited at both university/academic sites and at non-academic outpatient psychiatric service centers.
Depressive symptom severity was calculated via the Montgomery and Åsberg Depression Rating Scale (MADRS) and the Hamilton Rating Scale for Depression. Treatment response was defined as ≥50% MADRS total score reduction during application of 1 antidepressant agent for ≥4 weeks at an adequate dose, authors wrote, whereas “treatment resistance was defined by treatment failure of ≥2 consecutive adequate trials with antidepressants with or without agents for combination/augmentation.”
Detailed clinical interviews were carried out to gather sociodemographic information and clinical data. In addition, all participants exhibited physician-diagnosed migraine.
A total of 11.1% of 1410 participants exhibited comorbid migraine (95% CI: 9.4% to 12.7%), while the condition was found to be more common among females.
Researchers also found quality of life was significantly reduced in MDD patients with comorbid migraine, and this cohort tended to exhibit worse responses to the administered antidepressant therapy.
“Given multiple probable etiologic links, the lack of current guidelines for treating patients with MDD and migraine as comorbid condition is surprising and may even be mirrored in our findings regarding treatment strategies in the patient groups,” authors wrote.
The impact of migraine on treatment response and disability in MDD appears plausible while a reverse effect in terms of worsening migraine by poorly treated depression is also a reasonable assumption.
“Consequently, both diseases need to be sufficiently treated, at best as early as possible in terms of a patient-centered approach as described previously in the literature,” researchers concluded.
Fugger G, Dold M, Bartova L, et al. Clinical correlates and outcome of major depressive disorder and comorbid migraine: a report of the European group for the study of resistant depression. Int J Neuropsychopharmacol. Published online September 4, 2020. doi:10.1093/ijnp/pyaa035